Becton, Dickinson and Company (BDX) has demonstrated relative stability in the healthcare sector with a broad range of medical devices and diagnostic products. Recent analysts' ratings indicate a cautious but mostly positive outlook. The company's core segments support defensive investments, ideal for portfolios seeking stability amid market uncertainty.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 6 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
The sentiment around BDX has shown a shift toward more cautious stances over recent months. A decrease in "Strong Buy" recommendations reflects a growing market caution. Notably, "Hold" ratings have overtaken as analysts reassess market conditions.
The percentage of "Strong Buy" ratings decreased, with analysts gravitating towards neutral positions. The dominance of "Hold" suggests a repositioning towards caution, potentially anticipating more market volatility.
Over the past year, "Strong Buy" ratings have significantly decreased, reflecting apprehension likely due to macroeconomic factors.
Recent analyst recommendations highlight consistent views without significant changes in outlook. Most ratings have been maintained, illustrating steady market perception.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-05-11 | Overweight | Overweight | Barclays |
| 2026-05-08 | Equal Weight | Equal Weight | Wells Fargo |
| 2026-05-04 | Hold | Hold | TD Cowen |
| 2026-04-17 | Neutral | Neutral | Piper Sandler |
| 2026-03-26 | Neutral | Neutral | Piper Sandler |
There have been noteworthy adjustments in opinions over the past year, indicating a nuanced reevaluation of BDX's prospects. The movement from "Buy" to "Neutral" signals a re-assessment of growth projections.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-22 | Neutral | Buy | Citigroup |
| 2025-05-02 | Neutral | Overweight | Piper Sandler |
| 2025-05-01 | Market Perform | Outperform | William Blair |
| 2024-10-01 | Buy | Neutral | Citigroup |
| 2023-07-24 | Outperform | Market Perform | Raymond James |
The data implies that while BDX continues to benefit from positive sentiment, there are emerging signs of caution among analysts. The consistency in recommendations, primarily leaning towards "Hold", hints at an anticipation of market stagnation or slight declines. The lack of substantial downgrades to "Sell" or "Strong Sell" indicates that while confidence may be waning, pessimism isn't prevalent. Stability exists, but so does cautious optimism, signaling an environment of uncertainty with potential upside if conditions stabilize.
Becton, Dickinson and Company's analyst ratings reflect a balance between stability and cautious repositioning in response to broader market conditions. The shift from aggressive to neutral stances highlights market dynamics impacting BDX's perceived growth potential. Analysts remain steady with "Hold" recommendations, representing both a trust in BDX's consistent performance and apprehension regarding future growth. Overall, BDX stands as a potential safe harbor with room for positive revaluation, contingent on economic recoveries and stability in healthcare demands.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.